MT Newswires10d agoneutral
Sector Update: Healthcare Stocks Rise Late AfternoonHealthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index and the State
Actualités
Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
39last 24h
1801last 7d
299● bullish (7d)
170● bearish (7d)
205publishers
InvestorsHub10d agobullish
Eli Lilly stock jumps as GLP-1 sales widen Novo leadKey takeawaysEli Lilly’s second-quarter revenue surged 48 per cent to US$22. 97 billion, beating Wall Street expectations by more than US$2 billion.
GuruFocus.com10d agobearish
Novo Nordisk Stock Falls 4% Despite Stronger GLP-1 OutlookNovo raised its guidance, but pipeline impairments and slower product development kept investors focused on its competitive position.
The Wall Street Journal10d agoneutral
💬 Money Quote: Novo Nordisk CEO📣"I don't know the needs of the two competitors that are right now trying to talk to each other, but we don't see a need for a transformative M&A right now." —Mike Doustdar, CEO of Ozempic maker Novo Nordisk in an interview with the Journal, referring to a recent Financial Times report that AstraZeneca and Bristol Myers Squibb held talks over a tie-up.
MT Newswires10d agoneutral
Sector Update: Healthcare Stocks Advance Wednesday AfternoonHealthcare stocks were higher Wednesday afternoon, with the NYSE Healthcare Index rising 1.1% and th
The Wall Street Journal10d agoneutral
Health Care Roundup: Market TalkBUSINESS The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 0429 ET – Novo Nordisk’s second-quarter earnings beat and guidance raise imply minimal changes to the midpoint of consensus estimates, Bernstein analysts write.
Pharmaceutical Technology10d agoneutral
Novo Nordisk not currently in a position to pursue large-scale M&A, CEO saysSet against the backdrop of a mixed Q2, Novo is eyeing bolt-ons in favour of transformative acquisitions.
Zacks10d agoneutral
LLY Q2 Earnings Top, GLP-1 Drugs Fuel Growth, Sales Guidance RaisedLLY crushes Q2 earnings estimates and lifts its 2026 sales outlook as Mounjaro and Zepbound fuel strong revenue growth and newer drugs add momentum.
Zacks10d agobullish
AMGN Beats on Q2 Earnings, Lifts Outlook Despite Legacy Drug PressureAmgen beats Q2 earnings and revenue estimates and lifts its 2026 outlook. Key products witness strong growth despite biosimilar pressure on older drugs.
MT Newswires10d agoneutral
European Equities Traded in the US as American Depositary Receipts Edge Up in Wednesday TradingEuropean equities traded in the US as American depositary receipts were edging higher late Wednesday
Moby10d agoneutral
Novo Nordisk Swallows the Bitter PillThe Wegovy maker raised its outlook, but investors focused on pricing pressure, a pill sales miss and another pipeline stumble.
Yahoo Finance Video10d agoneutralVIDEO
Eli Lilly is treating nearly 10% of US obesity population with GLP-1s: CFOAfter the company reported second quarter earnings and raised its full-year sales guidance, Eli Lilly (LLY) CFO Lucas Montarce outlines the expansion opportunities that the pharmaceutical giant is seeing in its GLP-1 category, specifically the introduction of oral weight-loss drugs to the market.
Zacks10d agobullish
NVO Stock Down Despite Q2 Earnings and Sales Beat on GLP-1 GrowthNovo Nordisk beats Q2 earnings and sales estimates as GLP-1 demand grows, but pricing pressure, outlook concerns and pipeline setbacks sent shares lower.
Simply Wall St.10d agoneutral
Novo Nordisk (CPSE:NOVO B) Stock Still Looks Like A Bargain As Shares Fell 48%Novo Nordisk stock has given investors a mixed ride, with solid 1 year gains but a sharp decline over 3 years, even as the broader valuation checks still suggest the shares lean cheap compared with fundamentals. Recent news on blockbuster diabetes and obesity drugs on one side and a failed late stage cardiovascular trial on the other keeps the market focused on what price fairly reflects this balance. Over the past 3 years the share price is down 48.1%, which means long term holders are...
The Wall Street Journal10d agoneutral
Novo Nordisk CEO Remains Open to Bolt-On Acquisitions, But Rules out Transformative DealsChief Executive Mike Doustdar’s comments come amid sector focus on M&A and after Novo Nordisk made two disclosures in recent days on its future pipeline that disappointed investors.
Reuters Videos10d agoneutralVIDEO
Novo Nordisk looks to future proof as investors worry over pipeline<body><p>STORY: :: Novo Nordisk</p><p>'''Right now, the market isn't convinced that Novo Nordisk pipeline of experimental drugs is robust enough to fight against Lilly.''</p><p>:: How is Novo Nordisk future proofing as investors worry about pipeline?</p><p>:: August 5, 2026</p><p>:: Maggie Fick, European Pharma Industry Correspondent </p><p>''The drugmaker on Tuesday raised its full year profit and sales outlook, but investors are less focused on the numbers. They did look at the weaker than expected sales for its new Wegovy pill, and they're more focused on what the answer that the company has is to this question of the expirations of the patents for the company's key drugs. ''</p><p>'''So the name of the game now really is the medicines that Novo Nordisk is testing right now in trials. And also on Tuesday, Novo reported a trial failure for one of its next generation obesity drugs, obesity and diabetes drugs, CagriSema, and we think that's part of the reason that shares fell on these announcements.''</p><p>:: What is CEO Mike Doutsdar's response?</p><p>:: Novo Nordisk</p><p>''So Mike Doustdar acknowledged these recent trials setbacks, but he argued that they don't change the company's strategy. He says the answer is to move faster in research. He's been at the helm of the company now for a year. And he said one of the important steps he took was to combine research and development under one executive, and that that is helping that department move faster with trials. And he continues to say that failures are part of the pharmaceutical industry, that, trials are run with risks and so this is not unusual and they just have to keep moving. He said that it's important for Novo to stick to its strategy of bolt-on acquisitions to complement its own research and development. And he stressed that a transformational acquisition, a big merger, is not something on his agenda and that's for companies that have big problems.''</p></body>
Financial Times10d agobullish
Eli Lilly and Novo Nordisk raise profit outlook as demand for weight-loss drugs soarsEli Lilly and Novo Nordisk, the world’s two largest makers of weight-loss and diabetes drugs, raised their full-year forecasts on the back of...
Barrons.com10d agoneutral
Lilly Stock Jumps on Earnings Beat as Mounjaro Revenue Nearly DoublesEli Lilly posted a blockbuster second quarter fueled by continued demand for its portfolio of GLP-1 medications. The world’s biggest drugmaker by market value reported adjusted earnings of $8.38 a share in the period, better than the $6.01 consensus estimate among analysts polled by FactSet. Revenue surged 48% to nearly $23 billion—Wall Street was looking for $20.7 billion.
Investing.com10d agobullish
CVS shares jump on earnings beat, raised full-year guidanceInvesting.com -- CVS Health shares jumped about 5% in premarket trading Wednesday after the company raised its full-year profit guidance following better-than-expected second-quarter results.
Reuters10d agobullish
Eli Lilly raises annual revenue forecast as obesity, diabetes drug demand stay strongAug 5 () - Eli Lilly and Co raised its full-year revenue forecast on Wednesday, banking on sustained demand for its blockbuster GLP-1 weight-loss and diabetes drugs. The move comes less than a day after rival Novo Nordisk also hiked its full-year profit and sales forecast, banking on its oral Wegovy pill to help claw back lost ground from Lilly in the lucrative obesity market.
InvestorsHub10d agobearish
Novo Nordisk shares fall despite improved outlook as Wegovy sales disappointNovo Nordisk (NYSE:NVO) raised its full-year guidance after reporting continued demand for its weight-loss treatments, but weaker-than-expected sales of its oral Wegovy medication and disappointing clinical trial results for a next-generation obesity therapy weighed heavily on investor sentiment. The company’s shares dropped 6% during US trading on Tuesday, while its Copenhagen-listed stock declined 4.
InvestorsHub10d agoneutral
Middle East optimism lifts sentiment as SpaceX and AMD earnings dominate attention: Dow Jones, S&P, Nasdaq, Wall Street FuturesUS stock futures edged higher on Wednesday as investors reacted to renewed hopes of easing tensions in the Middle East, while corporate earnings from SpaceX (NASDAQ:SPCX), Advanced Micro Devices (NASDAQ:AMD) and Novo Nordisk (NYSE:NVO) drove significant pre-market trading. Although geopolitical developments supported overall market sentiment, investors also assessed company-specific news, particularly Elon Musk’s latest comments, which weighed on both SpaceX and AMD shares.
Barrons.com10d agobullish
European Stocks Extend Record HighsEuropean stock indexes were rising at the open, extending a raft of record highs. Industrial and retail stocks jumped as the Europe-wide Stoxx 600 rises 0.5% to 659.75 points, a new record. London's FTSE 100 popped 0.
Reuters10d agobullish
European shares edge higher as investors await progress in Mideast talksAugust 5 (Reuters) - European shares rose on Wednesday as investors monitored corporate earnings and diplomatic efforts to end the U.S.-Iran war and reopen the blockaded Strait of Hormuz.
The Wall Street Journal10d agobullish
Temasek-Backed Manipal Health Shares Surge in Indian Trading DebutThe hospital chain raised almost $1 billion in India’s second-largest initial public offering so far this year.
Investing.com10d agobearish
Novo Nordisk tumbles as Wegovy sales miss, trial setback overshadow raised outlookInvesting.com -- Novo Nordisk (CSE:NOVOb) (NYSE:NVO) hiked its full-year guidance, saying annual sales and operating profit should decline less than previously expected as demand for its weight-loss drugs continues unabated.
Proactive10d agobearish
FTSE 100 Live: Next and Glencore provide results boost, SpaceX tumblesFTSE 100 up 19 points to 10,899 Oil prices waver as Hormuz deal mooted SpaceX's earnings beat runs into a $116bn problem Next, Glencore, Legal & General, 4imprint, S4 Capital among results S&P services PMI due today 9.43am: Some L&G analysis L&G shares fell 1.2%...
Reuters10d agobullish
India's Manipal Health jumps 10.5% in market debut, valued at $9 billionAug 5 () - India's Manipal Health Enterprises made its market debut at a 10.5% premium on Wednesday, valuing the hospital chain at 857.
Stocktwits11d agobearish
NVO Stock Drops 6% Despite Raised Guidance As Investors Worry About Injectable GLP-1 Sales FutureNovo now expects underlying sales and operating profit in the range of 0% to –6% for the year.